Stemline Therapeutics Inc. (NASDAQ:STML) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stemline Therapeutics Inc.	N/A	995.72	85.02M	-3.00	0.00
Paratek Pharmaceuticals Inc.	17.12M	10.81	112.36M	-3.64	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Stemline Therapeutics Inc. and Paratek Pharmaceuticals Inc.

Profitability

Table 2 shows Stemline Therapeutics Inc. and Paratek Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Stemline Therapeutics Inc.	0.00%	-114.5%	-90.2%
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%

Risk and Volatility

Stemline Therapeutics Inc. is 12.00% more volatile than S&P 500 due to its 1.12 beta. Competitively, Paratek Pharmaceuticals Inc. is 71.00% more volatile than S&P 500, because of the 1.71 beta.

Liquidity

Stemline Therapeutics Inc. has a Current Ratio of 4.6 and a Quick Ratio of 4.6. Competitively, Paratek Pharmaceuticals Inc.’s Current Ratio is 11.4 and has 11.4 Quick Ratio. Paratek Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Stemline Therapeutics Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Stemline Therapeutics Inc. and Paratek Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Stemline Therapeutics Inc.	0	0	4	3.00
Paratek Pharmaceuticals Inc.	0	0	4	3.00

The upside potential is 137.51% for Stemline Therapeutics Inc. with average target price of $29. Meanwhile, Paratek Pharmaceuticals Inc.’s average target price is $21.25, while its potential upside is 272.15%. Based on the analysts belief we can conclude, Paratek Pharmaceuticals Inc. is looking more favorable than Stemline Therapeutics Inc.

Insider and Institutional Ownership

Institutional investors held 51.3% of Stemline Therapeutics Inc. shares and 77.7% of Paratek Pharmaceuticals Inc. shares. About 9.4% of Stemline Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 3.1% of Paratek Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Stemline Therapeutics Inc.	-4.36%	3.16%	8.46%	-31.27%	-31.88%	20.11%
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%

For the past year Stemline Therapeutics Inc. was less bullish than Paratek Pharmaceuticals Inc.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.